semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Gastric Cancer Leukemia Chronic Myelogenous Leukemia Patients with CML in chronic phase, accelerated phase based on cytogenetic abnormalities in addition to Philadelphia chromosome but with less than 5 % blasts, or GIST taking imatinib Patients with life expectancy of at least 12 months; patients must be on imatinib at time of study entry Ability to sign informed consent and/or assent  Patients with a known parathyroid disorder; active thyroid disorder except stable, replaced hypothyroidism; Cushing's syndrome; uncontrolled diabetes mellitus (could have unexpected fluid, electrolyte and mineral shifts); sarcoidosis (elevated calcitriol levels from granulomata); hypercalcemia of malignancy (i.e., PTHrP-mediated or extensive bone mets);known tumor-induced osteomalacia; Paget's disease of bone; known X-linged or autosomal dominant hypophosphatemic rickets/osteomalacia; known renal tubular disease (e.g., Fanconi's syndrome); chronic GI malabsorption sydrome Patients taking oral calcium in excess of calcium 750 mg and Vitamin D 400 mg daily (ie, that contained in a single multivitamin). Patients taking more than these amounts may be eligible for this study if vitamin and mineral supplementation in excess of this is stopped for a minimum of 2 weeks prior to study entry Patients taking oral or intravenous steroids, calcitonin, any selective estrogen modulating agent such as tamoxifen or raloxifene, gallium nitrate, and other bone seeking radionuceotides, any calcimimetic agent such as cinacalet Patients who have had prior treatment with cisplatin, carboplatin, oxaliplatin, ifosfamide, or cyclophosphamide
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hyperphosphatemia Most recent phosphorus and mean phosphorus over last 3 months > 5.5 mg/dL Age ≥ 18 years On chronic hemodialysis ≥ 6 months English speaking  Mentally incompetent AIDS Cancer Terminal illness Pregnancy Nursing home residence No telephone access In another phosphorus related study Unable to identify written words
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 20.0-40.0,  Sacroiliac Joint Pain Ages between 20 and 40 Ability to maintain normal balance Willingness to undergo HVLA manipulation to the SI Joints Normal blood pressure  Any visual or vestibular condition or systemic illness that would affect balance Any recent surgery, unstable joints of the lower extremity, recent hip and knee joint replacements or fitted hip or knee pins, bolts and/or plates Currently have any infection, acute inflammation, recent wounds, injury, tumors or other malignancy Currently taking any medications; prescription or herbal muscle stimulants, relaxants, etc A history of acute disc herniation, discopathy or spondylolysis A history of acute thrombosis, serious cardiovascular disease, diabetes, have irregular heartbeats(arrhythmia) or wear a pacemaker Any implanted device or prosthesis type of device Any Spinal manipulation within 48 hours Ages under 20 and over 40 Estimated BMI greater than 30
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Patients must be >18 with relapsed or refractory acute myeloid leukemia (AML) and high risk (by IPSS scoring) Myelodysplastic Syndromes (MDS) Patients with secondary AML or therapy related disease (t-AML) are eligible If decitabine or Vidaza was a prior treatment for MDS or AML patient is eligible.Prior Velcade is also permitted ECOG performance status 0-2 Life expectancy > 6 months for patients with a co-morbid medical illness Total bilirubin < 2.0mg/dL AST/ALT < 2.5 times upper limit of normal (ULN) Creatinine < 2.0 mg/dL Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception prior to and during study treatment  History of allergic reactions attributed to compounds of similar chemical or biologic composition to azacytidine or bortezomib that are not easily managed Hypersensitivity to bortezomib, boron, or mannitol Uncontrolled intercurrent illness including, but not limited to Symptomatic congestive heart failure Unstable angina pectoris Serious cardiac arrhythmia Psychiatric illness/social situations that would limit compliance with study Myocardial infarction within 6 months prior to enrollment New York Heart Association (NYHA) Class III or IV congestive heart failure Uncontrolled angina
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hemophilia Factor XIII Deficiency Patients may be of either sex or age. Children and newborn infants are specifically included in this study Patient must have documented congenital Factor XIII deficiency Patient or legal guardian must sign informed consent Patients who have negative serology for hepatitis B should receive Hepatitis B vaccination  Patient has acquired Factor XIII deficiency
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hyperparathyroidism, Secondary Kidney transplant recipient > 18 year/old with reduced and stable kidney function (estimated GFR 25-60 ml/min/1.73m2) iPTH levels between 120 and 500 pg/ml Stable immunosuppressive therapy (5-10 mg Prednisone/day, stable dosage of calcineurin inhibitors, or other immunosuppressive agents for at least 6 months)  Recent rejection episode (< 3 months) One of the following: baseline estimated GFR>60 ml/min/1.73m2 or <25 ml/min/1.73m2, albumin-corrected Ca>9.5 mg/dl or serum phosphorus >4.6 mg/dl Recipients of dual transplant organs with exception of kidney-pancreas Patients already receiving treatment with Vitamin D analogues Severe peripheral vascular disease or coronary artery disease History of previous parathyroidectomy Current alcohol or drug abuse Pregnant or nursing woman or female of child-bearing age not receiving contraception Other comorbidities that in the opinion of the investigators would reduce expected patient's survival and preclude study completion Medications that could interfere with Hectorol® metabolism
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Kidney Disease ≥ 18 years old Patient with pre-dialysis CKD attending the Progressive Renal Disease Clinic (PRDC) at St. Michael's Hospital Six-month mean serum phosphorus > 1.35 mmol/L Able to provide informed consent  Currently on dialysis Current malignancy Inability to use Phosphorus Point System (PPS) Tool
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Post Menopausal Arthralgia Postmenopausal women Already on upfront Arimidex Therapy (Start 1-4 weeks before) HR+  Premenopausal women Tamoxifen switch patients
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Secondary Hyperparathyroidism Dialysis Male and female participants > 18 years of age, with chronic kidney disease (CKD) stage V Participants with diagnosis of calcitriol resistance defined as: Episodes of hypercalcemia and/or hyperphosphatemia (defined as an episode of calcium or phosphorus above Upper Limit of Normal or documented by medical history stating that the treatment with calcitriol was discontinued due to hypercalcemia and/or hyperphosphatemia) that precludes treatment continuation and/or persistent PTH above 600pg/mL during the calcitriol therapy PTH value at screening visit between 600 pg/mL and 2,000 pg/mL Stable clinical conditions Participant has voluntarily consented to participate in the study, by signing and dating an informed consent form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), after the nature of the study has been explained and all his questions about the study have been elucidated. The informed consent must be signed before any study-specific procedures are performed  Previous parathyroidectomy Presence of hypercalcemia (corrected Ca > 10.5 mg/dL) and/or hyperphosphatemia (P > 6.0 mg/dL) and/or Ca x P product > 60, at screening visit (corrected Ca calculated by: [4 participant's serum albumin (g/dL)] x 0.8 + participant's serum Ca value) Severe and/or unstable clinical conditions, e.g., congestive heart failure, advanced cancer, advanced HIV disease, severe endocrinopathies, uncompensated diabetes mellitus, life-threatening cardiac arrhythmias, etc Abnormal liver tests (> 1.5 times above upper limit of normal) Pregnant or breast-feeding women Evidence of vitamin D toxicity Known hypersensitivity to any study drug components
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vitamin D Deficiency Primary Hyperparathyroidism Hypercalcemia P-Ca-ion > 1,30 mmol/l P-PTH > 5 pmol/l P-OH25-vitamin D < 80 nmol/l  P-creatinin > 120 mumol/l usage of Etalpha, Mimpara Cancer Sarcoidosis malabsorption pancreatitis alcohol abuse pregnancy
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 21.0-65.0,  Vitamin D Deficiency Age > 20 years Residence of Delhi Commitment for follow-up at 8 weeks, 6 months & 1 year Consent for 8 weeks of supplementation  Subjects taking drugs, which can affect bone mineral metabolism such as glucocorticoids, antitubercular, antiepileptics, levothyroxine, bisphosphonates Chronic renal or liver disorder Chronic diarrhea
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Advanced Cancer Patient with advanced cancer (local recurrence or metastatic) at the time of their follow up visit to the outpatient palliative care clinic or at an agreed date after the first visit to the outpatient palliative care clinic. 2. Patient designates a family member who is a patient's parent, spouse, adult child, sibling, other relative, or significant other (any other person defined by the patient as a partner) to answer the family questionnaire. 3. Patient is 18 years of age or older (as the assessment tools used in this study have not been validated in the pediatric population). 4. Patient with normal cognitive status as determined by the interviewer and by her/his ability to understand the nature of the study and consent process. 5. Patient willing to participate in the study and sign informed consent. 6. Family member is 18 years of age or older (as the assessment tools used in this study have not been validated in the pediatric population). 7. Family member with normal cognitive status as determined by the interviewer and by her/his ability to understand the nature of the study and consent process. 8. Family member willing to participate in the study and sign informed consent. 9. All participants in the international centers must be from Argentinian, Chilean, or Guatemalan descendence respectively. 10. All participants in the U.S. must be from self-reported Hispanic descendence, first or second generation immigrants, and reside in the U.S. for at least 5 years  Either patient or family member can not complete the assessments independently. 2. Either patient or family member refuses to participate in the study
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  End Stage Renal Disease Hemodialysis Inflammatory Response Cardiovascular Disease Patient stable on chronic hemodialysis for more than 3 months PTH level between 150 pg/ml Ability to give informed consent Serum calcium levels (corrected for albumin level of 4.0 g/dL) less than 10.5 mg/dL for the last three consecutive measurements Serum Phosphorus levels between 2.5 and 7.0 mg/dL for the last three consecutive measurements Ca x P-Product of less than 75 mg2/dL2 in the last three consecutive measurements  Known active malignancy Liver disease defined as serum aspartate aminotransferase, alanine aminotransferase, or gamma-glutamyltransferase levels more than 2 times the upper limits of normal PTH levels between 150 pg/mL and 800 pg/mL Hypercalcemia or hypercalcemic episodes within the last 4 weeks Ca x P-Product more than 75 mg2/dL2 within the last 4 weeks Any clinical significant infections which are or have been treated with antibiotics within 6 weeks prior to start of the study Chronic viral infection (HIV, Hepatitis B or C) Currently on immunosuppressive medication (steroids, cyclosporine, etc…) Hematocrit less than 30 % History of blood disorders other than renal anemia
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 20.0-55.0,  Hypophosphatemia Healthy man, who are between 20-55 years old, and have a BMI 20-27 kg/m2  Serum creatinin >100 mmol/L, or glomerular filtration rate <80 ml/min Abnormal serum Ca, PO4, albumin, 25-OH vitamin D, or PTH levels Any medication
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hip Disability Groin Disability Hip and/groin pain more than 6 weeks Physically active  Systemic diseases Physically inactive
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 6.0-16.0,  HIV Infection Bone Mass Subject, parent, or legal guardian able and willing to provide informed consent/assent. Subject able and willing to comply with requirements of study HIV-infected subjects must have diagnosis confirmed with one or more of the following tests: 1) HIV DNA Polymerase chain reaction or HIV culture performed at any age; 2) Age >18 months, licensed ELISA with confirmatory Western Blot  Patients with history of atraumatic fractures, known renal or liver disease, known malabsorption syndrome, or inflammatory bowel disease. Use of corticosteroids, exculding inhaled steroids (current or within past 6 months) Current use of anticonvulsant drug Daily cigarette smoking Daily consumption of alcohol containing beverages Current use of tenofovir
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Joint Abnormalities clinically ordered arthrogram  pregnant women children under the age of 18
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Healthy Subjects Vitamin D Deficiency Age 18-80  Known active infectious disease or chronic inflammatory disorder Hypercalcemia Chronic kidney disease Pregnancy
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Osteoporotic Vertebral Fracture Between T5 and L5 Chronic Arthritis, Longer Than Six Weeks Duration Patient is able to undergo the vertebroplasty or Balloon kyphoplasty procedure Patient has read and sign the informed consent Male or female, 50 years or older One or two non-traumatic vertebral fracture(s) Of osteoporotic origin (low speed trauma such as fall from his own height or less than 80 cm) Fracture(s) older than 6 weeks duration after the onset of pain related to the fracture· The fracture(s) exhibit(s) high signal intensity on T2-weighted images and a benign appearance at MRI Persistent pain despite medical treatment according to VAS ≥ 5 or a last resort to morphine treatment The patient will be able to receive the selected protocol treatment within 15 days after treatment randomization The benign nature of the vertebral fracture has to be confirmed by the results of the biopsy performed during vertebroplasty or balloon kyphoplasty  Patient with a vertebral fracture of less than 6 week duration after onset of fracture-related symptoms Neurological signs related to the vertebral fracture to treat History of surgical or percutaneous spine treatment except simple discectomy at a single or multiple vertebral levels with no residual pain Patient with more than 2 fractures corresponding to the (old fractures are not taken into account) Known allergy to a contrast media or to one of the cement components used for kyphoplasty More than two recent vertebral fractures Current infection Impossibility to perform the percutaneous approach of the vertebra to treat Known allergy to a contrast media or to one of the cement components used for kyphoplasty Reduction by more than 50% of the anteroposterior width of the bony spinal canal due to the vertebral fracture to treat